• Estrella Immunopharma posted a net loss of approximately $2.3 million for the three months ended March 31, 2026, widening from about $2.1 million a year earlier.
• Research and development expense edged down to about $1.4 million from roughly $1.41 million in the year-ago quarter.
• General and administrative costs climbed 28.5% to approximately $0.9 million.
• Cash and cash equivalents totaled about $1.9 million at March 31, 2026, with a working capital deficit of roughly $6.8 million.
• STARLIGHT-1 reached 10 patients dosed as of March 31, 2026, with about $8.3 million accrued for outstanding dosing milestone payments to Eureka.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-058063), on May 18, 2026, and is solely responsible for the information contained therein.